CN108245616A - A kind of glycometabolism adjustment sheet containing pure plant and preparation method thereof - Google Patents
A kind of glycometabolism adjustment sheet containing pure plant and preparation method thereof Download PDFInfo
- Publication number
- CN108245616A CN108245616A CN201611249171.3A CN201611249171A CN108245616A CN 108245616 A CN108245616 A CN 108245616A CN 201611249171 A CN201611249171 A CN 201611249171A CN 108245616 A CN108245616 A CN 108245616A
- Authority
- CN
- China
- Prior art keywords
- parts
- glycometabolism
- adjustment sheet
- extract powder
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000023852 carbohydrate metabolic process Effects 0.000 title claims abstract description 31
- 238000002360 preparation method Methods 0.000 title description 11
- 239000000463 material Substances 0.000 claims abstract description 29
- 241000522254 Cassia Species 0.000 claims abstract description 23
- 241000196324 Embryophyta Species 0.000 claims abstract description 18
- 235000002722 Dioscorea batatas Nutrition 0.000 claims abstract description 15
- 235000006536 Dioscorea esculenta Nutrition 0.000 claims abstract description 15
- 240000001811 Dioscorea oppositifolia Species 0.000 claims abstract description 15
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 claims abstract description 15
- 239000003814 drug Substances 0.000 claims abstract description 15
- 239000002994 raw material Substances 0.000 claims abstract description 14
- 239000000203 mixture Substances 0.000 claims abstract description 11
- 239000000843 powder Substances 0.000 claims description 36
- 239000000284 extract Substances 0.000 claims description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 20
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 10
- 235000019359 magnesium stearate Nutrition 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 10
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 10
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 10
- 241000037831 Polygonatum sibiricum Species 0.000 claims description 9
- 229940104640 chinese yam extract Drugs 0.000 claims description 9
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 8
- 239000003085 diluting agent Substances 0.000 claims description 8
- 238000000605 extraction Methods 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- 239000000314 lubricant Substances 0.000 claims description 7
- 238000007873 sieving Methods 0.000 claims description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 5
- 229920002472 Starch Polymers 0.000 claims description 4
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 4
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 4
- 238000001694 spray drying Methods 0.000 claims description 4
- 235000019890 Amylum Nutrition 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims description 2
- 239000004375 Dextrin Substances 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 239000000741 silica gel Substances 0.000 claims description 2
- 229910002027 silica gel Inorganic materials 0.000 claims description 2
- 239000000377 silicon dioxide Substances 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000003595 mist Substances 0.000 claims 2
- 239000007921 spray Substances 0.000 claims 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 229910052749 magnesium Inorganic materials 0.000 claims 1
- 239000011777 magnesium Substances 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 20
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 abstract description 17
- 230000000694 effects Effects 0.000 abstract description 9
- 201000001421 hyperglycemia Diseases 0.000 abstract description 7
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 230000002195 synergetic effect Effects 0.000 abstract description 3
- 238000010521 absorption reaction Methods 0.000 abstract description 2
- 239000004480 active ingredient Substances 0.000 abstract description 2
- 238000009472 formulation Methods 0.000 abstract 1
- 241000252212 Danio rerio Species 0.000 description 28
- 239000008280 blood Substances 0.000 description 18
- 210000004369 blood Anatomy 0.000 description 18
- 230000006870 function Effects 0.000 description 13
- 230000002218 hypoglycaemic effect Effects 0.000 description 12
- 230000007812 deficiency Effects 0.000 description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
- 239000008103 glucose Substances 0.000 description 9
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 8
- 238000010171 animal model Methods 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- 241000251468 Actinopterygii Species 0.000 description 7
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 210000000496 pancreas Anatomy 0.000 description 6
- 230000003915 cell function Effects 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 206010002091 Anaesthesia Diseases 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 239000009636 Huang Qi Substances 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- 230000037005 anaesthesia Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 235000019640 taste Nutrition 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 244000046146 Pueraria lobata Species 0.000 description 3
- 235000010575 Pueraria lobata Nutrition 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 235000010216 calcium carbonate Nutrition 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 244000247747 Coptis groenlandica Species 0.000 description 2
- 235000002991 Coptis groenlandica Nutrition 0.000 description 2
- 244000241872 Lycium chinense Species 0.000 description 2
- 235000015468 Lycium chinense Nutrition 0.000 description 2
- 240000000249 Morus alba Species 0.000 description 2
- 235000008708 Morus alba Nutrition 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 244000197580 Poria cocos Species 0.000 description 2
- 235000008599 Poria cocos Nutrition 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000002459 blastocyst Anatomy 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229940126678 chinese medicines Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 210000004153 islets of langerhan Anatomy 0.000 description 2
- 230000013011 mating Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229960004329 metformin hydrochloride Drugs 0.000 description 2
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin hydrochloride Natural products CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- 238000011017 operating method Methods 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 230000004796 pathophysiological change Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 238000001223 reverse osmosis Methods 0.000 description 2
- 238000012109 statistical procedure Methods 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 229940072040 tricaine Drugs 0.000 description 2
- FQZJYWMRQDKBQN-UHFFFAOYSA-N tricaine methanesulfonate Chemical compound CS([O-])(=O)=O.CCOC(=O)C1=CC=CC([NH3+])=C1 FQZJYWMRQDKBQN-UHFFFAOYSA-N 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010049865 Achromotrichia acquired Diseases 0.000 description 1
- 244000307697 Agrimonia eupatoria Species 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 241000432767 Asparagus setaceus Species 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 241000345998 Calamus manan Species 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 240000005250 Chrysanthemum indicum Species 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 241000601164 Clematis orientalis Species 0.000 description 1
- 244000077995 Coix lacryma jobi Species 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 229920002245 Dextrose equivalent Polymers 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 240000006509 Gynostemma pentaphyllum Species 0.000 description 1
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 241000545744 Hirudinea Species 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 240000007890 Leonurus cardiaca Species 0.000 description 1
- 235000000802 Leonurus cardiaca ssp. villosus Nutrition 0.000 description 1
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000361919 Metaphire sieboldi Species 0.000 description 1
- 235000009811 Momordica charantia Nutrition 0.000 description 1
- 240000001910 Momordica cochinchinensis Species 0.000 description 1
- 235000009812 Momordica cochinchinensis Nutrition 0.000 description 1
- 235000018365 Momordica dioica Nutrition 0.000 description 1
- 244000183278 Nephelium litchi Species 0.000 description 1
- 241000237502 Ostreidae Species 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241000405414 Rehmannia Species 0.000 description 1
- 240000007651 Rubus glaucus Species 0.000 description 1
- 235000011034 Rubus glaucus Nutrition 0.000 description 1
- 235000009122 Rubus idaeus Nutrition 0.000 description 1
- 240000006079 Schisandra chinensis Species 0.000 description 1
- 235000008422 Schisandra chinensis Nutrition 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 241000218989 Trichosanthes Species 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000000125 common agrimony Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000011697 diabetes animal model Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 201000005630 leukorrhea Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 235000020636 oyster Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108010008359 protein kinase C lambda Proteins 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 235000012950 rattan cane Nutrition 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000000837 restrainer Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000011820 transgenic animal model Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 206010046901 vaginal discharge Diseases 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a kind of glycometabolism adjustment sheets containing pure plant, are made of the raw material and pharmaceutically acceptable auxiliary material that contain following parts by weight, in terms of the adjustment sheet of 1000 parts by weight, contained feed components and its content are:10 800 parts of Chinese cassia tree, 5 280 parts of Chinese yam, 5 240 parts of sealwort.A kind of glycometabolism adjustment sheet provided by the invention, Formulation is scientific and reasonable, and there is no incompatibility, active ingredient combination can play synergistic effect;It is convenient to take, conducive to absorption, work quick, can effectively reduce the hyperglycemia of diabetic, and beta Cell of islet is promoted to regenerate, play treating both manifestation and root cause of disease effect, be it is a can the edible multi-selection product of medicine.
Description
Technical field
The present invention relates to a kind of food and field of health care food, more particularly to a kind of piece with glycometabolism adjustment effect
Agent, can Effective Regulation diabetes glucose and improvement islet beta cell function.
Background technology
According to statistics, global diabetic in 2014 is up to 3.87 hundred million people, dead 4,900,000 people, International Diabetes Federation
(IDF) it expects diabetic in 2035 and reaches 5.92 hundred million, increase by 55%[1].With the rapid development of economy, people live
The change of custom, in blowout situation, up to 1.14 hundred million, IDF in 2014 is expected 2035 to be increased China diabetic within nearly 10 years
1.43 hundred million are added to, China has become the most country of diabetic.Diabetes are one group of generations characterized by hyperglycemia
Thanking property disease, hyperglycemia be then since defect of insulin secretion or its biological effect are damaged, or both have concurrently and cause;70% pancreas
Island cell is β cells, can excreting insulin, play a part of to adjust blood glucose, if β cell functions are damaged, insulin secretion it is absolute or
Relative deficiency, so as to cause diabetes.Therefore, promote β cytothesises, improve islet cell function, just become prevention diabetes
Research hot topic.
The animal model of research diabetes mainly has 4 classes at present, respectively:Induction type animal model, spontaneous heredity are dynamic
Object model, pancreas part excision animal model and transgenic animal model.Using it is more be induction type animal model, but exist
Following deficiency:(1) processing of induction type diabetes animal model is various, lacks unified working specification;(2) weigh model into
Standard whether work(is irregular, and causing application factor influences model quality;(3) pathophysiological change of animal model and sugar
The pathophysiological change of the sick clinical patients of urine still has gap, and the theory of animal model cannot be entirely applied to clinical patients.
Zebra fish is a kind of common tropical fish, and due to raising, easy, embryo is transparent, in vitro fertilization, mutant variety is more, heredity
Many advantages, such as tool is ripe has become the emerging model animal of new drug development in recent years.Due to zebra fish gene and the mankind
The similarity of gene reaches 87%, it means that the obtained result of drug study is done with it and is also suitable in most cases
In human body[2-10].Research shows that zebra fish has, the homology of zebra fish pancreas and human pancreatic are very high, and the structure of pancreas
Similar with ingredient to the mankind, glucose-regulating mechanism is highly consistent with mammal, and the zebra fish diabetes model of structure is successfully commented
The hypoglycemic medicines such as valency biguanides, alpha-glucosidase restrainer and sulfonylureas, are as a result consistent with clinic[11-14]。
Present invention applicant carries out hypoglycemic effect using zebra fish diabetes model and promotees β cytothesis evaluation of effect, sees
Intuitive, analysis simplicity is examined, it is as a result objective reliable.
In presently commercially available hypoglycemic pcm or patent, equal existence component is complicated, and there are security risk, hypoglycemics for long-term use
The defects of mechanism of action is unclear, and hypoglycemic effect is imprecise.Such as hypoglycemic Tongmai Tablet, main component are:Radix pseudostellariae, Radix Astragali, sealwort,
Asparagus fern, Radix Ophiopogonis, radix scrophulariae, root of Chinese trichosanthes, rhizoma atractylodis, rhizoma anemarrhenae, pueraria lobata, the coptis, Radix Salviae Miltiorrhizae, motherwort, the radix paeoniae rubrathe, leech, radix cyathulae, chicken blood
Rattan, the root of Chinese clematis, semen litchi, earthworm, Rhizoma Chuanxiong, major function:Supplementing qi and nourishing yin, promoting blood circulation and removing blood stasis, clearing and activating the channels and collaterals, for deficiency of both vital energy and Yin,
It quenches one's thirst caused by obstruction of collaterals by blood stasis, drinks more, more foods, diuresis, becomes thin, weak and type-2 diabetes mellitus is shown in above-mentioned patient.For another example join stilbene
Melbine, main component are:Ginseng (cauline leaf) saponin(e, Schisandra chinensis, Radix Astragali, Chinese yam, glutinous rehmannia, raspberry, Radix Ophiopogonis, Poria cocos, smallpox
Powder, rhizoma alismatis, the fruit of Chinese wolfberry, major function:Supplementing qi and nourishing yin grows spleen kidney tonifying, diabetes is cured mainly, for type II diabetes.Patent document
Aspect, such as the Chinese invention patent of Publication No. CN101336974B disclose a kind of with overall regulation of body metabolism machine
Hypoglycemic fat-regulating Chinese medicine of energy and preparation method thereof, which is by Radix Astragali, gynostemma pentaphylla, pueraria lobata, mulberry leaf, faenum graecum, the coptis, Chinese cassia tree
Manufactured medicament in proportion.The for another example Chinese invention patent of Publication No. CN102861263B discloses a kind of pure Chinese medicine hypoglycemic
Preparation, the Chinese medicine be by Radix Astragali, sealwort, balsam pear, pueraria lobata, radix polygonati officinalis, the root bark of Chinese wolf-berry, Poria cocos, hairyvein agrimony, Chinese yam, oyster, Herba Epimedii,
Chrysanthemum, mulberry leaf, coix seed.The compound for reducing blood suger of above-mentioned existing antihypelipidemic product or patent literature, pharmacological mechanism
Do not consider from activation 'inertia' insulin, improvement islet beta cell function.
To sum up, how a kind of blood glucose of energy Effective Regulation diabetic population is provided, and is effectively improved the pancreas of diabetic population
The glycometabolism adjustment sheet containing pure plant of island β cell functions is that those skilled in the art are badly in need of the technical barrier solved.
Invention content
Present invention aims at a kind of glycometabolism adjustment sheet preparation method containing pure plant is provided, can not only drop
Hypoglycemia, it is without side-effects, can effectively activate 'inertia' insulin, and protect islet cells, and mild in medicine property and, be easy to absorb,
It is the pure Chinese medicine antihypelipidemic preparation for treating diabetes, solves and above-mentioned be previously mentioned related defects in the prior art.
For achieving the above object, this invention takes following technical schemes:
A kind of glycometabolism adjustment sheet containing pure plant, by containing the raw material of following parts by weight and pharmaceutically acceptable
Auxiliary material forms, and in terms of the adjustment sheet of 1000 parts by weight, contained feed components and its content are:10-800 parts of Chinese cassia tree, Chinese yam
5-280 parts, 5-240 parts of sealwort.
Preferably, extract powder is made in the raw material in a manner of extracting.
It is furthermore preferred that the raw material extract powder is made by the following method:Suitable Chinese cassia tree or Chinese yam or sealwort are taken, is added
Water extracts n times, merges the extracting solution that extracts every time, filters, and is concentrated under reduced pressure, be spray-dried to get.
It is furthermore preferred that in the extract powder extraction process, times N >=2 of extraction, extraction time is 1~4 hour.
Preferably, the auxiliary material include diluent and lubricant, wherein diluent for microcrystalline cellulose, starch, dextrin,
One or more of amylum pregelatinisatum, calcium sulfate, calcium monohydrogen phosphate, medicinal calcium carbonate, mannitol;Lubricant for magnesium stearate,
One or more of superfine silica gel powder, talcum powder and silica.
It is furthermore preferred that being made of in the auxiliary material diluent and lubricant, wherein diluent is microcrystalline cellulose, is lubricated
Agent is magnesium stearate.
Preferably, it is made of the raw material and pharmaceutically acceptable auxiliary material that contain following parts by weight, with 1000 parts by weight
Adjustment sheet meter, contained feed components and its content are:10-800 parts of Chinese cassia tree, 5-280 parts of Chinese yam, 5-240 parts of sealwort, crystallite
20-975 parts of cellulose, 5-20 parts of magnesium stearate.
A kind of method for preparing the glycometabolism adjustment sheet containing pure plant as previously described, includes the following steps:
1) appropriate Chinese cassia tree is taken, extracting in water 2 times, 1~4 hour every time, the quantity of solvent added by first time extracting in water was medicine
6~30 times of amount of material weight, the solvent added for the second time are 5~25 times of medicinal material weight;Merge extracting solution, filtration is depressurized dense
Contracting, spray drying, obtains Chinese cassia tree extract powder;
2) appropriate Chinese yam is taken, extracting in water 2 times 1~4 hour every time, adds the quantity of solvent added by extraction with aqueous solution for the first time
It is 6~30 times of amount of medicinal material weight, the solvent added for the second time is 6~25 times of medicinal material weight, merges extracting solution, and filtration subtracts
Pressure concentration, spray drying obtain Chinese yam extract powder;
3) appropriate sealwort is taken, extracting in water 2 times, 1~4 hour every time, the water added by first time extracting in water was medicinal material
6~20 times of water of weight, the water added for the second time are 5~15 times of medicinal material weight, merge extracting solution, and filtration is depressurized dense
Contracting, spray drying, obtains huang jing extract powder;
4) take respectively recipe quantity step 1), 2) and 3) made from Chinese cassia tree extract powder, Chinese yam extract powder and huang jing extract powder,
Add in auxiliary material, mix, sieving, direct tablet compressing to get.
The prescription principle and advantage of the present invention is as follows:
1st, Chinese cassia tree, Chinese yam and sealwort are to be embodied in 2015 editions in prescription《Chinese Pharmacopoeia》Medical and edible dual purpose plant, easily
It obtains, and without any toxicity, three taste Chinese medicines are at 2015 editions《Chinese Pharmacopoeia》In function it is specific as follows with curing mainly:
Chinese cassia tree:It mends fire and helps PFK guiding fire to origin, eliminating cold to stop pain, warm promoting menstruation, for positive fistula Gong Leng, waist Teng's crymodynia, kidney Virtual makees
Asthma, Virtual sun float, dizziness hot eyes , Xin Peep crymodynias, cold of insufficiency type vomiting and diarrhea, pain of trembling with fear abdominal pain, dysmenorrhoea Amenorrhea.
Chinese yam:Tonifying spleen nourishing the stomach, engender liquid and benefic lung, the puckery essence of kidney tonifying.For spleen eating less, endless diarrhea, the deficiency syndrome of the lung is breathed with cough, and kidney deficiency is lost
Essence, under, frequent micturition, abnormal heat is quenched one's thirst.Rhizoma Dioscoreae (parched with bran) good efficacy to suffering from a deficiency of the kidney.For spleen eating less, diarrhea loose stool, leukorrhea.
Sealwort:Boosting qi and nourishing yin, invigorating the spleen, moistening lung, kidney-nourishing.For deficiency of spleen-QI and stomach-QI, fatigue and asthenia, deficiency of stomach-Yin, dry deficiency of food,
Deficiency syndrome of the lung cough caused by dryness, overstrain cough hemoptysis, asthenia of essence and blood, soreness and weakness of waist and knees, poliosis, Heat Diabetes.
2nd, this three tastes Chinese medicine of Chinese cassia tree, Chinese yam and sealwort is respectively provided with different pharmacological actions, has different classes of cure mainly
Function is to be combined comprising three taste Chinese medicines in presently commercially available antihypelipidemic product.The present invention has found through investigative test, by Chinese cassia tree,
Chinese yam and three taste Chinese medicine of sealwort are combined jointly, and monarch, minister, the adjutant division of labor are clear and definite, can be synergistic, activate 'inertia' pancreas islet
Element has apparent facilitation to beta Cell of islet regeneration, therefore can have significant function of reducing blood sugar.
3rd, pure plant glycometabolism adjustment sheet of the invention, is a kind of oral conventional tablet, by the prescription system of the present invention
Into this one dosage type low temperature, considered based on following:1. dosage is accurate;2. stable quality;3. production mechanization, high degree of automation;4. it takes
With, carry, storage it is convenient, good mouthfeel, it is good that patient takes compliance;5. absorb rapid, quick acting.
In short, a kind of pure plant glycometabolism adjustment sheet provided by the invention, is mainly made of medical and edible dual purpose plant, place
Design is scientific and reasonable for side, and there is no incompatibility, active ingredient combination can play synergistic effect;For oral tablet, clothes
With conveniently, conducive to absorption, work quick, can effectively reduce the hyperglycemia of diabetic, and beta Cell of islet is promoted to regenerate, rise
To treating both manifestation and root cause of disease effect, be it is a can the edible multi-selection product of medicine.
Description of the drawings
Fig. 1 is blood sugar reducing function effect of this five kinds of glycometabolism adjustment sheets of the embodiment of the present invention 1~5.
Fig. 2 is rush beta Cell of islet palingenesis effect of this five kinds of glycometabolism adjustment sheets of the embodiment of the present invention 1~5.
Specific embodiment
The following is specific embodiments of the present invention, and technical scheme of the present invention is further described, but of the invention
Protection domain be not limited to these embodiments.It is every to be included in this hair without departing substantially from the change of present inventive concept or equivalent substitute
Within bright protection domain.
Embodiment 1:
Formula 1:In terms of 1000 parts,
10 parts of 5 parts of Chinese yam extract powders of Chinese cassia tree extract powder
5 parts of huang jing extract powder, 975 parts of microcrystalline cellulose
5 parts of magnesium stearate
Preparation process:Take the above-mentioned raw materials and auxiliary material of recipe quantity, mix, sieving, direct tablet compressing to get.Piece weight is 0.5g.
Embodiment 2:
Formula 2:In terms of 1000 parts,
110 parts of 70 parts of Chinese yam extract powders of Chinese cassia tree extract powder
60 parts of huang jing extract powder, 750 parts of microcrystalline cellulose
10 parts of magnesium stearate
Preparation process:Take the above-mentioned raw materials and auxiliary material of recipe quantity, mix, sieving, direct tablet compressing to get.Piece weight is 0.5g.
Embodiment 3:
Formula 3:In terms of 1000 parts,
220 parts of 140 parts of Chinese yam extract powders of Chinese cassia tree extract powder
120 parts of huang jing extract powder, 510 parts of microcrystalline cellulose
10 parts of magnesium stearate
Preparation process:Take the above-mentioned raw materials and auxiliary material of recipe quantity, mix, sieving, direct tablet compressing to get.Piece weight is 0.5g.
Embodiment 4:
Formula 4:In terms of 1000 parts,
330 parts of 210 parts of Chinese yam extract powders of Chinese cassia tree extract powder
180 parts of huang jing extract powder, 260 parts of microcrystalline cellulose
20 parts of magnesium stearate
Preparation process:Take the above-mentioned raw materials and auxiliary material of recipe quantity, mix, sieving, direct tablet compressing to get.Piece weight is 0.5g.
Embodiment 5:
Formula 5:In terms of 1000 parts,
720 parts of 60 parts of Chinese yam extract powders of Chinese cassia tree extract powder
60 parts of huang jing extract powder, 150 parts of microcrystalline cellulose
10 parts of magnesium stearate
Preparation process:Take the above-mentioned raw materials and auxiliary material of recipe quantity, mix, sieving, direct tablet compressing to get.Piece weight is 0.5g.
Embodiment 6:The blood sugar reducing function evaluation experimental of glycometabolism adjustment sheet of the present invention
1st, experimental animal
Wild type AB systems zebra fish, with fish culture water culture (breeding fish) water water quality under the conditions of 28 DEG C:It is reverse osmosis per 1L
200mg Instant Oceans are added in water, conductivity is 480~510 μ S/cm;PH is 6.9~7.2;Hardness is 53.7~71.6mg/L
CaCO3).4~5 pairs of zebra fish parent mating are taken, according to the method hatched blastocyst of Westerfield [15].The best of it will be in
The zebra fish in reason stage is placed under disecting microscope and observes, and the normotrophic zebra fish of picking is moved into 6 hole microwell plates.It has tested
Cheng Hou carries out over-exposure processing with the zebra fish of tricaine methanesulfonic acid pair, is put to death so as to which zebra fish be anaesthetized.What anesthesia was put to death
Operating procedure meets the code requirement that American Veterinary association (AVMA) puts to death Animal Anesthesia.
2nd, by reagent:
The 5 kinds of glycometabolism adjustment sheets prepared by the method for Examples 1 to 5 are labeled as formula 1, formula 2, match successively
Side 3, formula 4, formula 5.
3rd, laboratory apparatus and reagent
Metformin hydrochloride (Aladdin, 1127991);Alloxan (Sigma companies, 05760);Glucose (Jhansi Red
Star pharmaceutcal corporation, Ltd, S120720);Blood glucose meter (Accu-Che, Performa, Roche).
4th, experimental method
Wild type AB system zebra fish is randomly selected in 6 orifice plates, per 30 tail of hole, with alloxan and glucose Combined Treatment
Establish zebra fish hyperglycemia model;Water-soluble respectively to give formula 1, formula 2, formula 3, formula 4 and formula 5, concentration is 100 μ
G/mL, per hole 3mL liquids, positive controls are water-soluble to give melbine 10 μ g/mL concentration, while set Normal group and mould
Type control group.Zebra fish is collected after experiment, glucose content measure (S), statistical procedures result are carried out using blood glucose meter
It is represented with mean ± SE, adjustment sheet blood sugar reducing function calculation formula is as follows:Blood sugar reducing function (%)=[(S model control group-S test samples
Group) ÷ (S model control group-S Normal groups)] × 100%;With variance analysis and Dunnett ' s T- inspection carry out statistics
Analysis, p<0.05 shows with significant difference, provides representative experimental patterns.
5th, experimental result
Model control group zebra fish dextrose equivalent (3.76nmol/fish) is Normal group (1.1n mol/fish)
3.4 times, the two compares p<0.001, display zebra fish hyperglycemia model is successfully established;10 μ g/mL hypoglycemic rates of melbine are
19.55%, the p compared with model control group<0.05, display melbine has blood sugar reducing function.
This five kinds of glycometabolism adjustment sheets of the embodiment of the present invention 1~5, hypoglycemic rate difference 22.56%, 30.73%,
45.86%th, 39.85% and 36.09%, the p compared with model control group<0.01&p<0.001&p<0.001&p<0.001, display 5
Kind glycometabolism adjustment sheet has apparent blood sugar reducing function, and blood sugar reducing function is respectively from high to low:Formula 3>Formula 4>Formula 5>Match
Side 2>Formula 1, the results showed that:Formula 3 is optimization formula.
Refer to table 1 and Fig. 1.
1. glycometabolism adjustment sheet of table, 5 kinds of formula function of reducing blood sugar evaluation results (n=5)
Compared with model control group, * p<0.05,**p<0.01,***p<0.001
Embodiment 7:The rush beta Cell of islet palingenesis evaluation experimental of glycometabolism adjustment sheet of the present invention
1st, experimental animal
Transgenosis beta Cell of islet fluorescence zebra fish, with fish culture water culture (breeding fish) water water quality under the conditions of 28 DEG C:Often
200mg Instant Oceans are added in 1L reverse osmosis waters, conductivity is 480~510 μ S/cm;PH is 6.9~7.2;Hardness for 53.7~
71.6mg/L CaCO3).4~5 pairs of zebra fish parent mating are taken, according to the method hatched blastocyst of Westerfield [15].It will place
Zebra fish in the optimization process stage is placed under disecting microscope and observes, and the normotrophic zebra fish of picking moves into 6 hole microwell plates
In.After the completion of experiment, over-exposure processing is carried out with the zebra fish of tricaine methanesulfonic acid pair, is put to death so as to which zebra fish be anaesthetized.
The operating procedure that anesthesia is put to death meets the code requirement that American Veterinary association (AVMA) puts to death Animal Anesthesia.
2nd, by reagent:
The 5 kinds of glycometabolism adjustment sheets prepared by the method for Examples 1 to 5 are labeled as formula 1, formula 2, match successively
Side 3, formula 4, formula 5.
3rd, laboratory apparatus and reagent
Metformin hydrochloride (Aladdin, 1127991);Alloxan (Sigma companies, 05760);Glucose (Jhansi Red
Star pharmaceutcal corporation, Ltd, S120720);6 orifice plates (Nest Biotech, Chinese Shanghai);Fluorescence stereo microscope (SMZ645,
Nikon, Japan);Disecting microscope (SZX7, OLYMPUS, Japan);Power focus continuous zoom fluorescence microscope (AZ100,
Nikon, Japan).
4th, experimental method
Transgenosis beta Cell of islet fluorescence zebra fish is randomly selected in six orifice plates, per 30 tail of hole, with alloxan and grape
Sugared Combined Treatment establishes zebra fish hyperglycemia model.It is water-soluble respectively to give formula 1, formula 2, formula 3, be formulated 4 and formula 5, it is dense
Degree is 100 μ g/mL, per hole 3mL liquids, while sets Normal group and model control group.It is small that 28 DEG C of incubators are incubated 24
Shi Hou, every group takes 10 tail zebra fish to observe, take pictures under the microscope and preserves picture at random;Image is carried out with image analysis software
Analysis calculates zebra fish beta Cell of islet fluorescence intensity (S), carries out quantitative analysis, and statistical procedures result is represented with X ± SE;It adjusts
It is as follows that nodal plate promotees beta Cell of islet palingenesis calculation formula:β cytothesises rate (%)=(1-S test sample group ÷ S model comparisons
Group) × 100%;With variance analysis and Dunnett ' s T- inspection carry out statistical analysis, p<0.05 show it is poor with conspicuousness
It is different.
5th, experimental result
The fluorescence intensity (98264) of model control group p compared with Normal group (169919)<0.001, show zebra fish
The success of beta Cell of islet Establishing an injured model.5 kinds of glycometabolism adjustment sheet formula hypoglycemic rates difference 40.18%, 56.51%,
91.52%th, 76.08% and 60.09%, the p compared with model control group<0.01&p<0.001&p<0.001&p<0.001, display 5
Kind glycometabolism adjustment sheet has apparent rush beta Cell of islet regeneration effect, and effect is respectively formula 3 from high to low>Formula 4>Match
Side 5>Formula 2>Formula 1, as a result prompting formula 3 is optimization formula.
Refer to table 2 and Fig. 2.
2. glycometabolism adjustment sheet of table, 5 kinds of formulas promote beta Cell of islet palingenesis evaluation result (n=10)
Compared with model control group, * * p<0.01,***p<0.001
It is attached:Bibliography
[1]IDF.International Diabetes Federation.Retrieved 29November 2014.
[2]McGrath P,Li CQ.Zebrafish:a predictive model for assessing drug-
induced toxicity[J].Drug Discov Today,2008,13:394-401.
[3]He J H,Guo S Y,Zhu F,et al.A zebrafish phenotypic assay for
assessing drug-induced hepatotoxicity[J].J Pharmacol Toxicol Methods,2013,67:
25-32.
[4]Yang R,Lao QC,Yu HP,et al.Tween-80and Impurity Induce
Anaphylactoid Reaction in Zebrafish[J].J Appl Toxicol,2015,35:295-301.
[5]Xu M,Lao QC,Zhao P,et al.6′-O-Caffeoylarbutin inhibits
melanogenesis in zebrafish[J].Nat Prod Res,2014,28:932-934.
[6]Zhou J,Guo S Y,Zhang Y,et al.Human prokinetic drugs promote
gastrointestinal motility in zebrafish[J].Neurogastroenterol Motil,2014,26:
589-595.
[7]Zhu J J,Xu Y Q,He J H,et al.Human cardiotoxic drugs delivered by
soaking and microinjection induce cardiovascular toxicity in zebrafish[J].J
Appl Toxicol,2014,34:139-148.
[8]Zhou J,Xu YQ,Guo SY,Li CQ.Rapid analysis of hypolipidemic drugs in
a live zebrafish assay.J Pharmacol Toxicol Methods,2015,72:47-52.
[9]Li JL,Zhou J,Chen ZH,et al.Bioactive C 21Steroidal Glycosides from
the Roots of Cynanchum otophyllum That Suppress the Seizure-like Locomotor
Activity of Zebrafish Caused by Pentylenetetrazole.J Nat Prod.2015,24;78(7):
1548-1555.
[10]Xu H,Dong X,Zhang Z,et al.Assessment of immunotoxicity of dibutyl
phthalate using live zebrafish embryos.Fish&Shellfish Immunology,2015,45:286-
292.
[11]Pisharath H,Rhee JM,Swanson MA,et al.Targeted ablation of beta
cells in the embryonic zebrafish pancreas using E.coli nitroreductase.Mech
Dev.2007,124:218-29
[12]Elo B,Villano CM,Govorko D,White LA.Larval zebrafish as a model
for glucose metabolism:expression of phosphoenolpyruvate carboxykinase as a
marker for exposure to anti-diabetic compounds.J Mol Endocrinol.2007,38:433-
40.
[13]Jurczyk A1,Roy N,Bajwa R,et al.Dynamic glucoregulation and
mammalian-like responses to metabolic and developmental disruption in
zebrafish.Gen Comp Endocrinol.2011,15;170:334-45.
[14]Gut P,Baeza-Raja B,Andersson O,Hasenkamp L,et al.Whole-organism
screening for gluconeogenesis identifies activators of fasting metabolism.Nat
Chem Biol.2013,9:97-104
[15]Westerfield M.The Zebrafish Book:A Guide for the Laboratory Use
of Zebrafish.Eugene,Oregon:The University of Oregon Press,1993。
Claims (8)
1. a kind of glycometabolism adjustment sheet containing pure plant, by containing the raw material of following parts by weight and pharmaceutically acceptable auxiliary
Material composition, in terms of the adjustment sheet of 1000 parts by weight, contained feed components and its content are:10-800 parts of Chinese cassia tree, Chinese yam 5-
280 parts, 5-240 parts of sealwort.
2. the glycometabolism adjustment sheet according to claim 1 containing pure plant, which is characterized in that the raw material with
Extract powder is made in the mode of extraction.
3. the glycometabolism adjustment sheet according to claim 2 containing pure plant, which is characterized in that the raw material medicinal extract
Powder is made by the following method:Suitable Chinese cassia tree or Chinese yam or sealwort are taken, extracting in water n times merge the extracting solution extracted every time,
Filtration, be concentrated under reduced pressure, be spray-dried to get.
4. the glycometabolism adjustment sheet according to claim 3 containing pure plant, which is characterized in that the extract powder carries
In taking technique, times N >=2 of extraction, extraction time is 1~4 hour.
5. the glycometabolism adjustment sheet according to claim 1 containing pure plant, which is characterized in that the auxiliary material includes
Diluent and lubricant, wherein diluent are microcrystalline cellulose, starch, dextrin, amylum pregelatinisatum, calcium sulfate, calcium monohydrogen phosphate, medicine
With one or more of calcium carbonate, mannitol;Lubricant is in magnesium stearate, superfine silica gel powder, talcum powder and silica
It is one or more of.
6. the glycometabolism adjustment sheet according to claim 5 containing pure plant, which is characterized in that in the auxiliary material by
Diluent and lubricant composition, wherein diluent is microcrystalline cellulose, and lubricant is magnesium stearate.
7. according to the glycometabolism adjustment sheet according to any one of claims 1 to 6 containing pure plant, which is characterized in that by
Raw material containing following parts by weight and pharmaceutically acceptable auxiliary material composition, in terms of the adjustment sheet of 1000 parts by weight, contained original
Material each component and its content are:It is 10-800 parts of Chinese cassia tree, 5-280 parts of Chinese yam, 5-240 parts of sealwort, 20-975 parts of microcrystalline cellulose, hard
5-20 parts of fatty acid magnesium.
8. a kind of prepare such as the method for the glycometabolism adjustment sheet according to any one of claims 1 to 6 containing pure plant, packet
Include following steps:
1) appropriate Chinese cassia tree is taken, extracting in water 2 times, 1~4 hour every time, the quantity of solvent added by first time extracting in water was medicinal material weight
6~30 times of amount of amount, the solvent added for the second time are 5~25 times of medicinal material weight;Merge extracting solution, filter, be concentrated under reduced pressure, spray
Mist is dried, and obtains Chinese cassia tree extract powder;
2) appropriate Chinese yam is taken, extracting in water 2 times, 1~4 hour every time, for the first time plus the quantity of solvent added by extraction with aqueous solution was medicine
6~30 times of amount of material weight, the solvent added for the second time are 6~25 times of medicinal material weight, merge extracting solution, and filtration is depressurized dense
Contracting, spray drying, obtains Chinese yam extract powder;
3) appropriate sealwort is taken, extracting in water 2 times, 1~4 hour every time, the water added by first time extracting in water was medicinal material weight
6~20 times of water, second plus water be 5~15 times of medicinal material weight, merge extracting solution, filter, be concentrated under reduced pressure, spray
Mist is dried, and obtains huang jing extract powder;
4) take respectively recipe quantity step 1), 2) and 3) made from Chinese cassia tree extract powder, Chinese yam extract powder and huang jing extract powder, add in
Auxiliary material, mix, sieving, direct tablet compressing to get.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611249171.3A CN108245616A (en) | 2016-12-29 | 2016-12-29 | A kind of glycometabolism adjustment sheet containing pure plant and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611249171.3A CN108245616A (en) | 2016-12-29 | 2016-12-29 | A kind of glycometabolism adjustment sheet containing pure plant and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108245616A true CN108245616A (en) | 2018-07-06 |
Family
ID=62721633
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201611249171.3A Pending CN108245616A (en) | 2016-12-29 | 2016-12-29 | A kind of glycometabolism adjustment sheet containing pure plant and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108245616A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110714026A (en) * | 2019-10-22 | 2020-01-21 | 闽南师范大学 | Construction method and application of type II diabetic zebra fish model |
CN115364170A (en) * | 2022-10-20 | 2022-11-22 | 云南中医药大学 | Sugar metabolism regulator and preparation method and application thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102599518A (en) * | 2012-03-24 | 2012-07-25 | 青岛好管家商务有限公司 | Production method of specially-made sea cucumber capsule |
CN105435170A (en) * | 2015-12-11 | 2016-03-30 | 张量才 | Edible and medicinal traditional Chinese medicine health foodstuff |
-
2016
- 2016-12-29 CN CN201611249171.3A patent/CN108245616A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102599518A (en) * | 2012-03-24 | 2012-07-25 | 青岛好管家商务有限公司 | Production method of specially-made sea cucumber capsule |
CN105435170A (en) * | 2015-12-11 | 2016-03-30 | 张量才 | Edible and medicinal traditional Chinese medicine health foodstuff |
Non-Patent Citations (1)
Title |
---|
王群,等: "张志远教授治疗糖尿病经验", 《中国中医药现代远程教育》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110714026A (en) * | 2019-10-22 | 2020-01-21 | 闽南师范大学 | Construction method and application of type II diabetic zebra fish model |
CN115364170A (en) * | 2022-10-20 | 2022-11-22 | 云南中医药大学 | Sugar metabolism regulator and preparation method and application thereof |
CN115364170B (en) * | 2022-10-20 | 2023-01-24 | 云南中医药大学 | Sugar metabolism regulator and preparation method and application thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101559092B (en) | Application of eucommia ulmoides extracts | |
CN102614499B (en) | Yak skin collagen compound traditional Tibetan medicine with anti-fatigue effect and preparation process thereof | |
CN102988827A (en) | Dendrobium officinale granula | |
CN105031591B (en) | A kind of Chinese medicine composition and preparation method thereof for treating chronic renal failure | |
CN108245616A (en) | A kind of glycometabolism adjustment sheet containing pure plant and preparation method thereof | |
CN1267144C (en) | Compound diabetes-treating sugar-decreasing fat-reducing preparation and preparation method thereof | |
CN102813850B (en) | Traditional Chinese medicine composition for preventing and treating poultry coccidiosis and preparation method of traditional Chinese medicine composition | |
CN106177183A (en) | A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja, green tea and Folium Mori | |
CN112915131A (en) | Traditional Chinese medicine composition with fat burning function | |
CN105125946A (en) | Gardenia oral liquid clearing away heart fire and relieving restlessness and preparing method thereof | |
CN103251802A (en) | Appearance paste and preparation method thereof | |
CN101019897B (en) | Antitumor medicine composition and its preparation method | |
CN104623068B (en) | Treat medicine of fever in children infantile convulsion and preparation method thereof | |
CN104587175B (en) | A kind of Chinese medicine preparation for treating diabetes | |
CN102357151A (en) | Chinese medicinal composition for delaying senility and preparation process thereof | |
CN104257755A (en) | Composition with effect of treating diabetes as well as preparation method and application of composition | |
CN111528476A (en) | Compatible composition of ginseng and rhizoma polygonati honey tablets and preparation method | |
CN104107323B (en) | A kind of traditional Chinese medicinal composition with effect of reducing blood sugar and preparation method thereof | |
CN103932176A (en) | Health-care food composition for assisting to lower blood flat, as well as preparation method and application of composition | |
CN109528857A (en) | A kind of campanulaceae particle and preparation method thereof for treating respiratory disease caused by haze | |
CN105560694A (en) | Medicine composition for treating diabetic nephropathy and preparation method thereof | |
CN104983772B (en) | Blue lotus oral solution and preparation method thereof for animal warm heat disease initial stage | |
CN104587176B (en) | Treat the medicine of diabetes | |
CN103611046A (en) | Manufacturing method of composition for treating rumen indigestion | |
CN104606474B (en) | Treat the Chinese medicine of diabetes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180706 |
|
RJ01 | Rejection of invention patent application after publication |